Loading…
Evommune, Inc. is projected to rise to $13.32 by 2027, a +1% move from its current price of $13.21. EVMN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.52 | $13.22 | $13.95 | +0.06% |
| Jul 14 | $12.25 | $13.22 | $14.27 | +0.11% |
| Jul 15 | $12.05 | $13.23 | $14.53 | +0.17% |
| Jul 16 | $11.89 | $13.24 | $14.75 | +0.23% |
| Jul 17 | $11.74 | $13.25 | $14.94 | +0.28% |
| Jul 18 | $11.62 | $13.25 | $15.12 | +0.34% |
| Jul 19 | $11.50 | $13.26 | $15.29 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.50 | $13.26 | $15.29 | +0.40% |
| Week 2 | $10.88 | $13.31 | $16.29 | +0.79% |
| Week 3 | $10.44 | $13.37 | $17.11 | +1.19% |
| Week 4 | $10.09 | $13.42 | $17.85 | +1.60% |
| Week 5 | $9.80 | $13.47 | $18.53 | +2.00% |
| Week 6 | $9.54 | $13.53 | $19.18 | +2.40% |
| Week 7 | $9.31 | $13.58 | $19.80 | +2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evommune, Inc. is a clinical-stage biotechnology company operating in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Evommune, Inc. (EVMN) is currently priced at $13.29 per share, with a market cap of $478.68M. It ranks 3085 by market capitalization.
A major floor 69.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 90.6% above — a clean break opens room to run.
A major ceiling 125.1% above — clearing it would confirm fresh momentum.
Key EVMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.13 | Buy | $13.52 | Sell |
| MA 10 | $14.50 | Sell | $14.83 | Sell |
| MA 20 | $18.14 | Sell | $16.95 | Sell |
| MA 50 | $20.71 | Sell | $19.83 | Sell |
| MA 100 | $23.09 | Sell | $21.18 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.39 | Neutral |
| Stoch RSI (14) | 12.12 | Buy |
| CCI (20) | -75.61 | Neutral |
| Williams %R (14) | -93.37 | Info |
| MACD (12,26,9) | -0.58 | Sell |
| ROC (12) | -45.53 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 6.63 | Buy |
| TRIX (15) | -1.24 | Sell |
| Awesome (5,34) | -6.46 | Sell |
| Ultimate (7,14,28) | 40.96 | Neutral |
| Momentum (10) | -10.92 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 13.12 | Buy |
| ADX (14) | 27.39 | Sell |
| ATR (14) | 1.03 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30 and the SMA50 is $22.58. The 30-day price range runs from $8.76 to $20.17, with support at $13.29 and resistance at $25.18.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.36 | $13.21 | $19.68 | 0% | Neutral | |
| $8.70 | $13.32 | $22.05 | +1% | Neutral | |
| $8.18 | $13.89 | $25.03 | +5% | Neutral | |
| $10.96 | $20.41 | $39.20 | +55% | Bullish | |
| $10.12 | $20.56 | $41.59 | +56% | Bullish | |
| $8.05 | $17.79 | $37.62 | +35% | Bullish | |
| $8.55 | $18.99 | $41.76 | +44% | Bullish | |
| $7.56 | $16.79 | $38.21 | +27% | Bullish | |
| $8.62 | $19.16 | $44.06 | +45% | Bullish | |
| $11.86 | $26.35 | $60.60 | +99% | Bullish | |
| $11.21 | $24.92 | $57.31 | +89% | Bullish | |
| $27.03 | $60.08 | $138.18 | +355% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.36 | $13.21 | $16.15 | +0.00% |
| August 2026 | $10.85 | $13.50 | $17.71 | +2.19% |
| September 2026 | $10.93 | $13.91 | $18.80 | +3.04% |
| October 2026 | $10.19 | $13.21 | $18.31 | -5.02% |
| November 2026 | $9.94 | $13.10 | $18.52 | -0.86% |
| December 2026 | $10.21 | $13.66 | $19.68 | +4.33% |
Click any year to see its month-by-month EVMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Evommune, Inc.'s 2026 outlook centres on $13.21, within a $12.36 to $19.68 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EVMN could reach as high as $22.05, with a base case around $13.32 and support toward $8.70 — roughly +1% from $13.21. Price action looks broadly range-bound.
Expect EVMN to range from $8.18 to $25.03 through 2028. The $13.89 average target implies a +5% move from current prices. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
The EVMN price prediction for 2029 points to an average of $20.41 (low $10.96, high $39.20) — a potential gain of +55% on today's $13.21. Momentum favours further upside here.
In 2030, EVMN is projected to trade between $10.12 and $41.59, averaging $20.56 — a potential gain of +56% from today's $13.21. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Evommune, Inc.'s 2031 outlook centres on $17.79, within a $8.05 to $37.62 range. That is -13% versus the projected 2030 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2032, EVMN could reach as high as $41.76, with a base case around $18.99 and support toward $8.55 — roughly +44% from $13.21. Buyers look set to stay in control over this stretch.
Expect EVMN to range from $7.56 to $38.21 through 2033. The $16.79 average target implies a +27% move from current prices. That is -12% versus the projected 2032 average. Momentum favours further upside here.
The EVMN price prediction for 2034 points to an average of $19.16 (low $8.62, high $44.06) — a potential gain of +45% on today's $13.21. Buyers look set to stay in control over this stretch.
In 2035, EVMN is projected to trade between $11.86 and $60.60, averaging $26.35 — a potential gain of +99% from today's $13.21. That is up +38% on the projected 2034 average. Momentum favours further upside here.
Evommune, Inc.'s 2040 outlook centres on $24.92, within a $11.21 to $57.31 range. That is -5% versus the projected 2035 average. That marks a +89% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EVMN could reach as high as $138.18, with a base case around $60.08 and support toward $27.03 — roughly +355% from $13.21. Momentum favours further upside here.
Investing $1,000 in EVMN today (≈ 75.700227 EVMN) could be worth
$4,547.84
+$3,547.84 (+355%) by 2050 · US Dollar
Based on the average projected EVMN price of $60.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVMNwould be worth at today's price.
$1,000 invested in EVMN on Nov 6, 2025 (≈ 49.431538 EVMN) would be worth
$652.99
-$347.01 (-34.7%) today · 0.65× · US Dollar
Based on a EVMN entry price of $20.23 vs. today's $13.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.96 | $1,019.29 | +1.9% |
| 1 month ago | $20.49 | $644.7 | -35.5% |
| 3 months ago | $25.51 | $517.84 | -48.2% |
| 6 months ago | $21.14 | $624.88 | -37.5% |
| All time ago | $20.23 | $652.99 | -34.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVMN forecast.
Our base-case forecast reaches $26.00 around 2035.
Implied market cap at $26.00: $936.48M
The multi-year forecast spans 2026 to 2050, with a series of year-by-year average prices and ROIs. For 2026 the avg is $13.29 with ROI 0% and a min of $13.29 to a max of $19.75, while 2027 shows a negative ROI of -4.8% with avg $12.66 and a range of $8.24 to $21.01. In 2028 the avg rises to $13.65 (ROI 2.7%) with a range of $8.02 to $24.65, and 2029 projects an avg of $20.15 with ROI 51.6% (range $10.79 to $38.77).
2030 shows an avg of $19.84 and ROI 49.3% (range $9.74 to $40.20), followed by 2031 with avg $17.35 and ROI 30.6% (range $7.83 to $36.74) and 2032 with avg $18.44 and ROI 38.7% (range $8.30 to $40.58). 2033 carries an avg of $15.77 and ROI 18.6% (range $7.09 to $35.92), 2034 has avg $18.17 and ROI 36.7% (range $8.18 to $41.79), and 2035 shows a strong forward path with avg $24.96 and ROI 87.8% (range $11.23 to $57.41). The forecast continues with 2040 avg $23.70 and ROI 78.4% (range $10.67 to $54.52) and culminates in 2050 with avg $55.92 and ROI 320.8% (range $25.16 to $128.61).
Overall, sentiment shifts toward BULLISH in many later years, with notable upside potential but also periods of lower or negative returns in earlier years.
Tap a question to reveal the answer.
Avg price is $19.84 with a min of $9.74 and a max of $40.20. The forecast shows ROI of 49.3% and a BULLISH sentiment for 2030.
The forecast includes multiple bullish-years (e.g., 2029, 2030, 2031, 2032, 2034, 2035, 2040, 2050) with positive ROIs such as 51.6% in 2029 and 320.8% in 2050, but it also shows a negative ROI of -4.8% in 2027 and a neutral year in 2026 and 2033, illustrating that outcomes are uncertain.
The maximum forecast for 2050 is $128.61, reflecting potential upside but not a guarantee.
The current price is $13.29 and the market cap is $478.68M.
The 30-day range is $8.76 to $20.17. Support is $13.29 and resistance is $25.18.
Evommune, Inc. Community Discussion
0Share your Evommune, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.